Hand-foot syndrome or palmar-plantar erythrodysesthesia syndrome
- May 2022
- 15min
Therapeutic classes inducing this adverse event
Chemotherapy
CTCAE V5.0
Minimal skin changes or dermatitis (e.g., erythema, edema, or hyperkeratosis) without pain
SIMPLIFIED GRADING
Minimal skin changes
Painless
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
CTCAE V5.0
Skin changes (e.g., peeling, blisters, bleeding, fissures, edema, or hyperkeratosis) with pain; limiting instrumental ADL
SIMPLIFIED GRADING
Skin changes and moderate pain (VAS <6) or blistering or limiting instrumental ADL
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
CTCAE V5.0
Severe skin changes (e.g., peeling, blisters, bleeding, fissures, edema, or hyperkeratosis) with pain; limiting self care ADL
SIMPLIFIED GRADING
Severe skin changes and severe pain (VAS ≥ 6) OR Widespread blistering OR Limiting self care ADL, difficulty walking
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
Browse for more adverse events